Site Editor

Jeremy S. Abramson, MD, MMSc

Advertisement

Advertisement

News

Looking Beyond BTK Inhibitors and Venetoclax for Double-Refractory CLL

Medical Literature

What’s the Diagnosis? Positive Fecal Blood Test, Thrombocytopenia

Medical Literature

CLL Agents: Drug Interactions and Comorbidities

News

Relapsed or Refractory MCL: Brexucabtagene Autoleucel vs Allogeneic Transplant

Medical Literature

Warehouse-Based Vaccination Strategy in Patients With CLL: Trial Offers Proof of Concept

News

Mantle Cell Lymphoma: Comparing Outcomes With Time-Limited Initial Regimens

News

Factors Impacting Overall Survival Among Patients With CLL on Targeted Therapy

Videos

Matthew S. Davids, MD, MMSc, on TP53-Aberrant CLL: Combination of Acalabrutinib, Venetoclax, and Obinutuzumab

Videos

Jeremy S. Abramson, MD, MMSc, on MCL: Is There Still a Role for ASCT in Mantle Cell Lymphoma?

Advertisement

JNCCN Spotlights

(Update) Acalabrutinib in CLL and MCL

Zanubrutinib

(Update) Venetoclax in CLL

Acalabrutinib

Obinutuzumab

View More

More

News

Diagnostic and Insurance Disparities Among Minority Patients With Lymphoma

Early Research Findings on the Use of Zanubrutinib Plus Sonrotoclax in CLL

Acalabrutinib Combination Therapy Approved by FDA for Previously Untreated MCL

Long-Term Outcomes of CAR T-Cell Therapy in Responders With CLL

Impact of Immunosenescence on CAR T-Cell Treatment in CLL

European Study on Chemoimmunotherapy vs BTK Inhibitors in CLL

Combining Acalabrutinib and Rituximab in Older Patients With Mantle Cell Lymphoma

Venetoclax/Obinutuzumab May Improve PFS in CLL

View More

Advertisement

Published

Medical Literature

Novel CLL12 Study Investigates Outcomes With Ibrutinib in Early-Stage CLL

Zanubrutinib vs Ibrutinib for CLL in China: ALPINE Trial Subgroup

Is the Hematotox Score Predictive of Outcomes After CAR T-Cell Therapy?

Novel Case Report of Zanubrutinib Plus Radiotherapy for MCL Epidermoid Tumor

View More

Ongoing

CE Activities

Meet The Professor: William Wierda MD, PhD

An Interactive Case-Based Review of of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia

Navigating Patient-Centered Care of CLL and MCL: Empowering Collaboration and Communication

View More

Available

Clinical Trials

University of Nebraska

Siteman Cancer Center

Dana-Farber Cancer Institute

Duke Cancer Institute

View More

Resources

For Your Patients

Cancer.gov

Patient Power

UpToDate

Leukemia & Lymphoma Society

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2025 National Comprehensive Cancer Network, All Rights Reserved